academic article

• Key Exchange by Synchronization of two Chaotic Systems.  Inorganic Chemistry Communications.  141:109606. 2022
• Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.  Computers in Biology and Medicine.  146:105526. 2022
• Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine–hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer.  Journal of Enzyme Inhibition and Medicinal Chemistry.  36:1290-1311. 2021
• Design and synthesis of pyrazolo[3,4-d]pyrimidinone derivatives: Discovery of selective phosphodiesterase-5 inhibitors.  Text categorization.  21:127337-182. 2020
• Design, synthesis, and biological evaluation of new pyrazoloquinazoline derivatives as dual COX‐2/5‐LOX inhibitors.  Archiv der Pharmazie.  353:2000027. 2020
• 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.  Bioorganic Chemistry.  89:102988. 2019
• Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.  Bioorganic & Medicinal Chemistry.  24:3501-3512. 2016
• Synthesis, 3D pharmacophore, QSAR and docking studies of novel quinazoline derivatives with nitric oxide release moiety as preferential COX-2 inhibitors.  MedChemComm.  6:283-299. 2015
• Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents.  Bioorganic Chemistry.  57:65-82. 2014
• Novel 1-[4-(Aminosulfonyl)phenyl]-1H-1,2,4-triazole derivatives with remarkable selective COX-2 inhibition: Design, synthesis, molecular docking, anti-inflammatory and ulcerogenicity studies.  European Journal of Medicinal Chemistry.  83:398-408. 2014
• Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.  European Journal of Medicinal Chemistry.  61:132-145. 2013
• Differentiating sepsis from non-infective systemic inflammatory response syndrome: Comparison between C-reactive protein and Leptin.  The Egyptian Journal of Critical Care Medicine.  1:111-118. 2013
• Phytol/Phytanic Acid and Insulin Resistance: Potential Role of Phytanic Acid Proven by Docking Simulation and Modulation of Biochemical Alterations.  PLoS ONE.  8:e45638. 2013
• Design, Synthesis and Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine CDK2 Inhibitors as Anti-tumor Agents.  Scientia Pharmaceutica.  79:429-447. 2011
• Novel Diphenylamine 2,4'-Dicarboxamide Based Azoles as Potential Epidermal Growth Factor Receptor Inhibitors: Synthesis and Biological Activity.  Chemical and Pharmaceutical Bulletin.  59:1124-1132. 2011
• Design, synthesis and docking studies of new furobenzopyranones and pyranobenzopyranones as photoreagent towards DNA and as antimicrobial agents.  European Journal of Medicinal Chemistry.  45:317-325. 2010
• Synthesis, biological evaluation and docking studies of novel benzopyranone congeners for their expected activity as anti-inflammatory, analgesic and antipyretic agents.  Bioorganic & Medicinal Chemistry.  17:5059-5070. 2009
• Tetrahydrobenzo- and benzofurobenzopyrones as a new class of potential photoreagents toward DNA.  European Journal of Medicinal Chemistry.  44:18-24. 2009
• Design and Synthesis of Novel Benzopyran-2-one Derivatives of Expected Antimicrobial Activity through DNA Gyrase-B Inhibition.  Archiv der Pharmazie.  341:725-733. 2008
• Design, synthesis, and docking studies of novel benzopyrone derivatives as H1-antihistaminic agents.  Bioorganic & Medicinal Chemistry.  16:9009-9017. 2008